A requirement for the development of iPS cell-based autologous cell therapy for MDs such as FKRP-associated dystroglycanopathies is the correction of underlying genetic mutations before the generation of myogenic progenitors. The gene discussed is FKRP; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.